Navigation Links
Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009
Date:10/15/2009

provement over negative EBITDA of $11.2 million in the prior year. The primary reasons for this improvement are more target-specific advertising and reduced general and administrative expenses.

The adverse financial results primarily reflect the severe economic downturn and caused the company to breach a financial covenant with its senior lender. The lender waived this breach upon agreement by the company to repay by November 15, 2009 all amounts borrowed from the lender. The company is also negotiating to restructure $2.5 million principal amount of notes plus interest that are past due and are secured by the company's Iceland Health trademark.

The company has signed a non-binding letter of intent for the sale of its retail and direct response businesses to a privately owned company and will announce the terms of the proposed sale if the transaction proceeds and when there is a binding agreement. The company will continue to refocus its main efforts on its profitable ingredients business.

The bid price for the company's common stock has been less than $1 for more than 30 consecutive days and, as a result, Nasdaq Staff notified the company on December 26, 2007 that it does not comply with Listing Rule 5550(a)(2). On October 9, 2009, Nasdaq Staff further notified the company that the period to regain compliance with the Rule expired October 7, 2009, and that unless the company appeals the Staff's determination, trading in the common stock will be suspended on October 20, 2009 and the common stock will be delisted. The company does not plan an appeal and expects that its common stock will be quoted on the OTC Bulletin Board.

About Nutrition 21

Nutrition 21, Inc. (NASDAQ: NXXI - News), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based a
'/>"/>

SOURCE Nutrition 21, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management
2. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
3. Salugen to Present at Nutrition Capital Networks First In-Person Investor Meeting
4. CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public
5. Pilot Therapeutics Announces New Executive Team with Extensive Experience Creating New Health and Nutrition Businesses
6. Salugen Expands U.S. Distribution and Announces a Partnership with DNA Dimensions to Bring DNA Customized Nutritional Solutions to Metro Detroit Area
7. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
8. Natural Nutrition Launches International Marketing Campaign for New All Natural Analgesic: BLUE LIGHTNING(TM) Fast Pain Relief
9. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
10. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
11. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... (Nasdaq:,SIAL) announced today the global release of ... researchers to reproducibly,interrogate gene function, via siRNA ... not been considered amenable to conventional lipid-based,siRNA ... reagents exhibit a number,of drawbacks, including high ...
... DIEGO, Oct. 18 Volcano Corporation,(Nasdaq: VOLC ) ... shares of its common stock at a price of ... by Volcano. Volcano has granted the,underwriters a 30-day option ... common stock to cover over-allotments, if any. The offering,is ...
... Oct. 17 AMICAS, Inc. (Nasdaq: AMCS ),a ... today announced it will present to and meet with ... being held in New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... -- Presentation begins promptly at 10:20 a.m. (Eastern ...
Cached Biology Technology:Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types 2Volcano Corporation Announces Pricing of Common Stock Offering 2
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... CitiusTech announced today that its BI-Clinical platform ... ACO quality measures that are part of the ACO ... BI-Clinical can now help ACO participants assess ... four domains - patient / caregiver experience, care coordination ...
... FLAGSTAFF, Ariz. More peer-reviewed scientific studies of ... and operations are needed to adequately assess their impact, ... literature review conducted by the U.S. Geological Survey and ... their literature review, the authors of the paper, USGS ...
... New findings by Virginie Stevens ( CNRS ), ... Naturelle ) and colleagues show that interactions between dispersal ... study was published as open access paper in the ... dispersal plays a key role in gene flow among ...
Cached Biology News:BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS 2Literature review on solar energy and wildlife impacts research 2Butterflies: 'Twice-punished' by habitat fragmentation and climate change 2
mIGSF4A Aff Pur PAb...
Human IL-19 MAb (Clone 152112)...
SRY (sex determining region Y)-box 10...
... Steel Staining tray 19 x 29 cm, ... and blot processing.Automated staining of Coomassie Blue ... acid analysis. Prepares blots for high sensitivity ... of protocol, solution, volume, and processing time.Proven ...
Biology Products: